Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Refractory Multiple Myeloma: Likelihood of Approval
Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for Refractory Multiple Myeloma....
Purinostat mesylate by Chengdu Zenitar Biomedical Technology for Relapsed Multiple Myeloma: Likelihood of Approval
Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for Relapsed Multiple Myeloma....
Purinostat mesylate by Chengdu Zenitar Biomedical Technology for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for T-Cell Acute Lymphocytic...
Purinostat mesylate by Chengdu Zenitar Biomedical Technology for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Purinostat mesylate is under clinical development by Chengdu Zenitar Biomedical Technology and currently in Phase I for B-Cell Acute Lymphocytic...